Debiopharm Group:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Debiopharm Group - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10784
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Debiopharm Group (Debiopharm) is a biopharmaceutical company that develops biologics and small molecule drug candidates. The company’s product portfolio includes eloxatin, elplat, dacotin, dacplat, decapeptyl, neo decapeptyl, trelstar, pamorelin, salvacyl and moapar, among others. It also offers services such as clinical development, manufacturing and quality assurance, regulatory services and innovative drug delivery and formulation, among others. Debiopharm targets therapy areas include colorectal cancer, ovarian cancer, breast cancer, prostate cancer and other sexual disorders, among others. The company has operations in Switzerland and Canada. Debiopharm is headquartered in Lausanne, Switzerland.

Debiopharm Group – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Debiopharm Group, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Debiopharm Group, Medical Devices Deals, 2012 to YTD 2018 9
Debiopharm Group, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Debiopharm Group, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 13
Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 14
Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 15
Venture Financing 17
ABAC Therapeutics Raises USD20 Million in Series A Financing 17
Immunexpress Raises US$6 Million In Venture Financing 19
Biocartis Raises US$40.5 Million In Series E Financing 20
Spinomix Raises US$3 Million In Series A Financing 22
Biocartis Raises US$44.7 Million In Series D Financing 23
Partnerships 25
Debiopharm Enters into Enters into Agreement with Paul Scherrer Institute 25
Debiopharm Partners with Merck and Pfizer 26
Debiopharm Enters into Distribution Agreement with Arbor Pharma 27
Debiopharm International Enters into Agreement with EORTC 28
United Labs Enters into Distribution Agreement with Debiopharm International 29
Debiopharm Enters into Agreement with Solid Biosciences 30
Debiopharm Enters into Co-Development Agreement with Nobelex Biotech 31
Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 32
Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 33
Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 34
Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 35
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 36
Licensing Agreements 37
Debiopharm International Enters into Licensing Agreement with Almac Discovery 37
Evotec Enters Into Licensing Agreement With Debiopharm 38
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 39
Debiopharm Enters Into Licensing Agreement With Yale University 40
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 41
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 42
Acquisition 43
Debiopharm To Acquire Pharma Company 43
Debiopharm Group – Key Competitors 44
Debiopharm Group – Key Employees 45
Debiopharm Group – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Debiopharm Group, Pharmaceuticals & Healthcare, Key Facts 2
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Debiopharm Group, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Debiopharm Group, Deals By Therapy Area, 2012 to YTD 2018 8
Debiopharm Group, Medical Devices Deals, 2012 to YTD 2018 9
Debiopharm Group, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Debiopharm Acquires Antibody Drug Candidate from ImmunoGen 13
Debiopharm International Acquires FibroTrap Sample Processing Technology from Spinomix 14
Debiopharm Group Acquires Antibiotic Clinical Assets and Technology Platform From Affinium 15
ABAC Therapeutics Raises USD20 Million in Series A Financing 17
Immunexpress Raises US$6 Million In Venture Financing 19
Biocartis Raises US$40.5 Million In Series E Financing 20
Spinomix Raises US$3 Million In Series A Financing 22
Biocartis Raises US$44.7 Million In Series D Financing 23
Debiopharm Enters into Enters into Agreement with Paul Scherrer Institute 25
Debiopharm Partners with Merck and Pfizer 26
Debiopharm Enters into Distribution Agreement with Arbor Pharma 27
Debiopharm International Enters into Agreement with EORTC 28
United Labs Enters into Distribution Agreement with Debiopharm International 29
Debiopharm Enters into Agreement with Solid Biosciences 30
Debiopharm Enters into Co-Development Agreement with Nobelex Biotech 31
Atheris Labs Enters Into Agreement With Debiopharm For Debio 0826 Optimization 32
Experimental Therapeutics And Debiopharm Enter Into Agreement To Develop Epigenetic Oncology Target 33
Debiopharm International And TCG Lifesciences Enter Into Research Agreement To Develop Antibiotics 34
Cenix BioScience And Debiopharm Enter Into Agreement To Develop Drug Candidates 35
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 36
Debiopharm International Enters into Licensing Agreement with Almac Discovery 37
Evotec Enters Into Licensing Agreement With Debiopharm 38
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 39
Debiopharm Enters Into Licensing Agreement With Yale University 40
Shasun Pharma Enters Into Licensing Agreement With Debiopharm 41
Debiopharm Enters Into Licensing Agreement With Ascepion Pharma For Kinase Inhibitor, ASP-08126 42
Debiopharm To Acquire Pharma Company 43
Debiopharm Group, Key Competitors 44
Debiopharm Group, Key Employees 45
Debiopharm Group, Subsidiaries 46

List of Figures
Debiopharm Group, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Debiopharm Group, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Debiopharm Group, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Debiopharm Group, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Debiopharm Group:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Realtech A.G. (RTC):企業の財務及び戦略的SWOT分析
    Summary REALTECH AG (REALTECH) is a technology company that provides software solutions to monitor and manage enterprise-wide IT systems. The company develops, implement, operates and support IT strategy, transition, design and operations. It provides services such as portfolio management, assessmen …
  • Diploma PLC (DPLM):企業の財務及び戦略的SWOT分析
    Summary Diploma PLC (Diploma) is a business organization that specializes in technical products and services. The organization conducts business through the segments such as life sciences, seals and controls. Its life sciences segment supplies consumables, instrumentation and related services to the …
  • Visonic Ltd.:企業の戦略的SWOT分析
    Visonic Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Repsol S.A. (REP):企業のM&A・提携動向(石油・ガス分野)
    Summary Repsol S.A. (Repsol) is an integrated oil and gas company. It explores for, develops and produces crude oil and natural gas; transports oil products, liquefied petroleum gas (LPG) and natural gas; refines and produces petroleum products; and retails oil products, oil derivatives, petrochemic …
  • AlteAd:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' AlteAd Mergers and Acquisitions …
  • Siemens AG:企業の戦略・SWOT・財務情報
    Siemens AG - Strategy, SWOT and Corporate Finance Report Summary Siemens AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Deutsche Telekom AG (DTE):企業の財務・戦略的SWOT分析
    Deutsche Telekom AG (DTE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Involys SA (INV):企業概要、財務及び戦略的SWOT分析
    Summary Involys SA (Involys) is a software solution provider. The company designs and develops software solutions. Its product PRAXIS is an asset management solution for inventory valuation and maintenance of real estate and equipment assets. Involys provides asset management, expenditure management …
  • Munchener Ruckversicherungs-Gesellschaft AG (Munich Re):戦略・SWOT・企業財務分析
    Munchener Ruckversicherungs-Gesellschaft AG (Munich Re) - Strategy, SWOT and Corporate Finance Report Summary Munchener Ruckversicherungs-Gesellschaft AG (Munich Re) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the compan …
  • Voltamp Transformers Limited (VOLTAMP):企業概要、財務及び戦略的SWOT分析
    Summary Voltamp Transformers Limited (Voltamp) is an electric equipment manufacturing company. The company designs, manufactures, markets, and distributes oil filled power and distribution transformers. Its products include oil filled transformers, cast resin transformers, unitised sub-station, indu …
  • NH Foods Ltd.:企業の戦略・SWOT・財務情報
    NH Foods Ltd. - Strategy, SWOT and Corporate Finance Report Summary NH Foods Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Clean Energy Fuels Corp (CLNE):石油・ガス:M&Aディール及び事業提携情報
    Summary Clean Energy Fuels Corp (Clean Energy) is an oil and gas company that offers natural gas fuel transportation services. The company’s products fuels, liquefied natural gas, compressed natural gas, renewable natural gas, and bulk fuels. It also provides storage systems, compressors, dispensers …
  • Abraxas Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Abraxas Corporation Mergers and …
  • Residential Capital, LLC:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Residential Capital, LLC Merger …
  • Prosperity Minerals Holdings Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Prosperity Minerals Holdings Li …
  • ITOCHU Corporation:企業の戦略・SWOT・財務情報
    ITOCHU Corporation - Strategy, SWOT and Corporate Finance Report Summary ITOCHU Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Theralase Technologies, Inc. (TLT):企業概要、財務及び戦略的SWOT分析
    Summary Theralase Technologies, Inc. (TTI) is a medical device company. The company designs, develops and manufactures laser and laser technology for human, companion animal and equine applications. Its products include lasers, super pulsing technology and TLC-1000 and its components. TTI’s lasers a …
  • Daxor Corp (DXR):企業財務及び戦略的SWOT分析
    Summary Daxor Corp (Daxor) is a medical instrumentation and biotechnology company that manufactures blood volume analyzers. Its flagship product, BVA-100 blood volume analyzer is an instrument to measure human blood volume. It is used in conjunction with Volumex, a single-use radiopharmaceutical dia …
  • Buzzi Unicem SpA:戦略・SWOT・企業財務分析
    Buzzi Unicem SpA - Strategy, SWOT and Corporate Finance Report Summary Buzzi Unicem SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • PartnerRe Ltd.:企業の戦略・SWOT・財務情報
    PartnerRe Ltd. - Strategy, SWOT and Corporate Finance Report Summary PartnerRe Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆